A venture capital firm with offices in USA and Canada is considering opportunities for investment out its third, most recent fund. The firm leads or co-leads seed investments, typically in the $500K-$1.5M range, in seed – small A rounds, and will provide additional capital to portfolio companies of up to $8M from the primary fund and up to an additional $8M from the LP co-investment fund, over the life of the investment. The firm looks to make 3-5 investments per year.
The firm has invested in a variety of med-tech companies including a company with a drug delivery platform technology and a range of digital health companies. Moving forward the firm will be more focused on diagnostics, drug delivery and platform technologies capable of generating re-purposed drugs – emphasis placed on short sales cycles and de-risked assets. The firm is agnostic in regards to therapeutic type and will consider large and small molecules as well as re-purposed or biosimilar assets and platform technologies. The firm prefers to invest early in a therapeutic’s life cycle, typically in preclinical or phase I, and is opportunistic in terms of indication.
The firm only considers companies with experienced management teams, and requires a board seat with every investment.
If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment